^
    7d
    EGFR/KIT-linked proliferative bias in normal breast lobules from matched non-Hispanic Black and White women is rapidly reversible by RTK inhibition. (PubMed, Am J Pathol)
    Functional plausibility was assessed in pre-stasis human mammary epithelial cells (HMECs) exposed for 24 h to clinically relevant EGFR (lapatinib) or KIT (ripretinib) inhibitors. Together, matched normal tissue and primary-cell data indicate a coordinated EGFR/KIT-linked proliferative bias in NHBW epithelium that is rapidly reversible in vitro. These findings motivate composition-aware validation in larger normal-tissue cohorts and pharmacodynamic window studies to test whether short-term RTK modulation can reset proliferation-biased states in at-risk breast epithelium.
    Journal
    |
    EGFR (Epidermal growth factor receptor) • CDK4 (Cyclin-dependent kinase 4)
    |
    lapatinib • Qinlock (ripretinib)
    7d
    EMBARQ-CSU1: A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria (clinicaltrials.gov)
    P3, N=963, Active, not recruiting, Celldex Therapeutics | Recruiting --> Active, not recruiting
    Enrollment closed
    8d
    EMBARQ-CSU2: A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria (CSU) (clinicaltrials.gov)
    P3, N=976, Active, not recruiting, Celldex Therapeutics | Recruiting --> Active, not recruiting
    Enrollment closed
    12d
    A Phase 2, Open-Label, Extension Study to Evaluate Long Term Safety and Clinical Activity of Briquilimab in Participants From Jasper-Sponsored Chronic Urticaria Trials (clinicaltrials.gov)
    P2, N=67, Active, not recruiting, Jasper Therapeutics, Inc. | Enrolling by invitation --> Active, not recruiting | Trial primary completion date: Dec 2026 --> Aug 2026
    Enrollment closed • Trial primary completion date
    |
    briquilimab (JSP191)
    18d
    BLU-808-1201: Study of BLU-808 in Chronic Inducible Urticaria and Chronic Spontaneous Urticaria (2024-520031-33-00)
    P1/2, N=57, Recruiting, Blueprint Medicines Corp.
    New P1/2 trial
    18d
    CHILL-MC: A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Tolerability, Pharmacokinetic, Pharmacodynamic, and Preliminary Efficacy Trial of GTX-B001 in Healthy Volunteers (Part A) and Patients with Chronic Inducible Urticaria (Part B) (2025-522126-13-00)
    P1, N=56, Recruiting, Granular Therapeutics Limited
    New P1 trial
    18d
    300383: Phase 3 Study of IDRX-42 (GSK6042981) vs Sunitinib in Participants with Metastatic and/or Unresectable GIST after Imatinib (2025-522229-37-00)
    P2/3, N=148, Not yet recruiting, Glaxosmithkline Research & Development Limited
    New P2/3 trial
    |
    imatinib • sunitinib • velzatinib (GSK6042981)
    25d
    Study of BLU-808 in Allergic Rhinoconjunctivitis (clinicaltrials.gov)
    P2, N=21, Completed, Blueprint Medicines Corporation | Active, not recruiting --> Completed | N=54 --> 21 | Trial completion date: Dec 2025 --> Sep 2025 | Trial primary completion date: Dec 2025 --> Sep 2025
    Trial completion • Enrollment change • Trial completion date • Trial primary completion date
    25d
    A Study of Barzolvolimab in Patients With Atopic Dermatitis (clinicaltrials.gov)
    P2, N=131, Active, not recruiting, Celldex Therapeutics | Recruiting --> Active, not recruiting
    Enrollment closed
    29d
    INTRIGUE: A Study of Ripretinib vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib (clinicaltrials.gov)
    P3, N=453, Active, not recruiting, Deciphera Pharmaceuticals, LLC | Trial completion date: Dec 2025 --> Dec 2026
    Trial completion date
    |
    imatinib • sunitinib • Qinlock (ripretinib)
    30d
    Astragalus polysaccharide enhances the antitumor efficacy of sunitinib in renal cell carcinoma by targeting the ZEB1-SCD1-Wnt/β-Catenin signaling pathway. (PubMed, Int J Biol Macromol)
    Clinical data further verified that high ZEB1 expression is associated with poor prognosis in RCC and that ZEB1 promotes tumor progression by regulating SCD1 to activate the Wnt signaling pathway. In conclusion, APS enhances the sensitivity of RCC to sunitinib by targeting the ZEB1-SCD1-Wnt axis, thus providing a theoretical basis for the clinical application of this combined therapy.
    Journal
    |
    ZEB1 (Zinc Finger E-box Binding Homeobox 1)
    |
    sunitinib
    30d
    Glucosamine suppresses hepatocellular carcinoma progression through dual inhibition of cell cycle progression and nucleotide metabolism. (PubMed, Biochim Biophys Acta Mol Basis Dis)
    Collectively, our findings suggest GlcN as a potential therapeutic agent for HCC and underscore its chemosensitizing potential when combined with lenvatinib. Given GlcN's established clinical safety, this combination offers a translatable strategy for HCC therapy.
    Journal
    |
    E2F1 (E2F transcription factor 1)
    |
    Lenvima (lenvatinib)